Article Text

PDF
The International Intravitreal Bevacizumab Safety Survey
  1. F Ziemssen,
  2. S Grisanti,
  3. K U Bartz-Schmidt
  1. University Eye Hospital Tuebingen, Tuebingen, Germany
  1. Correspondence to: F Ziemssen University Eye Hospital Tuebingen, Schleichstr 12, D-72076 Tuebingen, Germany; Focke.Ziemssen{at}med.uni-tuebingen.de

Statistics from Altmetric.com

We read with interest the article by Fung et al1 assessing complications related to single or repeat intravitreal injections of bevacizumab. We congratulate the authors on studying this innovative treatment via the internet and greatly appreciate the effort to gather timely information about the potentially related adverse events. When using a product for an indication not in the approved label, doctors have the responsibility to be well informed about the product and its potential risks, and to base its use on firm scientific rationale and sound medical evidence.2 Informed consent must also depend on a full discussion of all potential complications of the treatment proposed. Unfortunately, some pitfalls of this survey have restricted the explanatory power of the presented results.3

The definition of the study population remains …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.